Market Highlights: Preclinical imaging is the design of live animals for research purposes such as drug development. Imaging techniques were essential for the researchers to observe changes at the organ, tissue, cell, or molecular level in animals that respond to physiological or environmental changes. Imaging modalities that are not aggressive and have become particularly important to examine animal models in the longitudinal direction. These imaging systems can be divided into mainly morphological/anatomical and mainly molecular imaging techniques. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) are commonly used for anatomical imaging, while optical imaging (fluorescence and bioluminescence), positron emission tomography (PET) and single-photon emission are calculated. Tomography (SPECT) is usually used for molecular visualizations used. The market study is being classified by Type (Fluorescence/ Bioluminescence Imaging Systems, Standalone Fluorescence Imaging Systems and Optical + X-Ray/Optical + CT), by Application (Pharma and Biotech Companies, Research Institutes, Hospital and Others) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Key Players: The prominent players in the Optical Preclinical Imaging Devices are ThermoFisher Scientific (United States), Bruker Corporation (United States), Perkin Elmer (United States), MR Solutions (United Kingdom), BioTek Instruments (United States), Milabs (Netherlands), FUJIFILM Visualsonics, Inc. (Canada), Magnetic Insight Inc. (United States), MBF Bioscience (United States), Mediso (Budapest), LI-COR Biosciences (United States), Aspect Imaging (Israel), TriFoil Imaging (United States) and Miltenyi Biotech GmbH (Germany).
Major Market Development Highlights In December 2019 Fujifilm to Acquire Hitachiís Diagnostic Imaging-related Business to Accelerate Growth of Its Healthcare Business. FUJIFILM Corporation announced that it has agreed with Hitachi, Ltd. to acquire Hitachiís Diagnostic Imaging-related Business to further expand its Healthcare business. Fujifilm will acquire all the outstanding shares of the New Company from Hitachi. The completion of this acquisition is subject to customary closing conditions and regulatory approvals.
Key Questions Answered in the Report What will the Optical Preclinical Imaging Devices Market size and the growth rate be in Future? What are the key factors driving the Optical Preclinical Imaging Devices Market? What are the key market trends and macro-economic impacting the growth of the Optical Preclinical Imaging Devices Market? What are the challenges to market growth? Who are the key vendors in the Optical Preclinical Imaging Devices Market? What are the market opportunities and threats faced by the vendors in the Optical Preclinical Imaging Devices Market? Trending factors influencing the market shares of the Players. What are the key outcomes of the five forces analysis of the Optical Preclinical Imaging Devices Market?
Research Methodology: The top-down and bottom-up approaches are used to estimate and validate the size of the Global Optical Preclinical Imaging Devices market. In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Optical Preclinical Imaging Devices market. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc. Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Providers of Optical Preclinical Imaging Devices, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others. This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc. Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.